Efficacy and Toxicity of Triweekly Versus Weekly Cisplatin in Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

This retrospective study compared the efficacy and toxicity of concurrent triweekly versus weekly cisplatin in patients with previously untreated, biopsy-proven NPC who received definitive CRT followed by adjuvant chemotherapy. Patients with distant metastasis, Karnofsky Performance Status < 80, induction chemotherapy, or no adjuvant therapy were excluded....

Continue reading at PubMed →

Audiologists involved in ototoxicity monitoring programs for head and neck cancer patients should note this comparison, as dosing schedule may influence the degree of cisplatin-related hearing damage — but the retrospective design limits definitive guidance.

Determining which cisplatin schedule causes less hearing damage without compromising cancer control is critical for audiologists co-managing ototoxicity surveillance in oncology settings.

1. 01Retrospective study comparing triweekly vs. weekly cisplatin in chemoradiotherapy for nasopharyngeal carcinoma.
2. 02Ototoxicity (medication-related hearing damage) is a clinically significant toxicity outcome examined in the study.
3. 03Published in International Journal of Cancer (PMID 42706851, DOI 10.1002/ijc.70723).
4. 04Findings could inform oncology team decisions affecting audiological monitoring protocols.
5. 05Retrospective design limits strength of causal conclusions about hearing outcomes.

PMID

42706851

DOI

10.1002/ijc.70723.

Journal

International Journal of Cancer

Publication type

research_article

Evidence level

2b

Population

Patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy

Intervention

Triweekly cisplatin in concurrent chemoradiotherapy

Comparator

Weekly cisplatin in concurrent chemoradiotherapy